vs
Alector, Inc.（ALEC）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
过去两年Alector, Inc.的营收复合增速更高（-37.4% vs -100.0%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
ALEC vs RVMD — 直观对比
营收规模更大
ALEC
是对方的Infinity倍
$0
两年增速更快
ALEC
近两年复合增速
-100.0%
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $0 |
| 净利润 | $-37.3M | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | -634.4% | — |
| 净利率 | -597.5% | — |
| 营收同比 | -88.5% | — |
| 净利润同比 | -1696.9% | -20.4% |
| 每股收益（稀释后） | $-0.34 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECRVMD
| Q4 25 | $6.2M | — | ||
| Q3 25 | $3.3M | — | ||
| Q2 25 | $7.9M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $54.2M | $0 | ||
| Q3 24 | $15.3M | $0 | ||
| Q2 24 | $15.1M | $0 | ||
| Q1 24 | $15.9M | $0 |
净利润ALECRVMD
| Q4 25 | $-37.3M | — | ||
| Q3 25 | $-34.7M | — | ||
| Q2 25 | $-30.5M | — | ||
| Q1 25 | $-40.5M | — | ||
| Q4 24 | $-2.1M | $-194.6M | ||
| Q3 24 | $-42.2M | $-156.3M | ||
| Q2 24 | $-38.7M | $-133.2M | ||
| Q1 24 | $-36.1M | $-116.0M |
营业利润率ALECRVMD
| Q4 25 | -634.4% | — | ||
| Q3 25 | -1153.6% | — | ||
| Q2 25 | -433.6% | — | ||
| Q1 25 | -1216.5% | — | ||
| Q4 24 | -13.4% | — | ||
| Q3 24 | -315.7% | — | ||
| Q2 24 | -302.4% | — | ||
| Q1 24 | -275.0% | — |
净利率ALECRVMD
| Q4 25 | -597.5% | — | ||
| Q3 25 | -1063.4% | — | ||
| Q2 25 | -387.7% | — | ||
| Q1 25 | -1101.6% | — | ||
| Q4 24 | -3.8% | — | ||
| Q3 24 | -275.2% | — | ||
| Q2 24 | -256.4% | — | ||
| Q1 24 | -227.0% | — |
每股收益（稀释后）ALECRVMD
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $-0.34 | — | ||
| Q2 25 | $-0.30 | — | ||
| Q1 25 | $-0.41 | — | ||
| Q4 24 | $-0.02 | $-1.13 | ||
| Q3 24 | $-0.43 | $-0.94 | ||
| Q2 24 | $-0.40 | $-0.81 | ||
| Q1 24 | $-0.38 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $2.3B |
| 总债务越低越好 | $10.0M | — |
| 股东权益账面价值 | $30.6M | $2.3B |
| 总资产 | $293.2M | $2.6B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALECRVMD
| Q4 25 | $256.0M | — | ||
| Q3 25 | $291.1M | — | ||
| Q2 25 | $307.3M | — | ||
| Q1 25 | $354.6M | — | ||
| Q4 24 | $413.4M | $2.3B | ||
| Q3 24 | $457.2M | $1.5B | ||
| Q2 24 | $503.3M | $1.6B | ||
| Q1 24 | $562.1M | $1.7B |
总债务ALECRVMD
| Q4 25 | $10.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALECRVMD
| Q4 25 | $30.6M | — | ||
| Q3 25 | $57.7M | — | ||
| Q2 25 | $71.2M | — | ||
| Q1 25 | $94.6M | — | ||
| Q4 24 | $126.8M | $2.3B | ||
| Q3 24 | $118.9M | $1.6B | ||
| Q2 24 | $150.6M | $1.6B | ||
| Q1 24 | $178.9M | $1.7B |
总资产ALECRVMD
| Q4 25 | $293.2M | — | ||
| Q3 25 | $335.3M | — | ||
| Q2 25 | $356.4M | — | ||
| Q1 25 | $408.3M | — | ||
| Q4 24 | $468.3M | $2.6B | ||
| Q3 24 | $516.0M | $1.8B | ||
| Q2 24 | $570.7M | $1.8B | ||
| Q1 24 | $635.5M | $1.9B |
负债/权益比ALECRVMD
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-139.5M |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-567.7M |
8季度趋势，按日历期对齐
经营现金流ALECRVMD
| Q4 25 | $-41.7M | — | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-49.0M | — | ||
| Q1 25 | $-60.8M | — | ||
| Q4 24 | $-55.0M | $-138.3M | ||
| Q3 24 | $-50.7M | $-130.4M | ||
| Q2 24 | $-62.8M | $-128.2M | ||
| Q1 24 | $-61.3M | $-160.6M |
自由现金流ALECRVMD
| Q4 25 | — | — | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-49.1M | — | ||
| Q1 25 | $-60.8M | — | ||
| Q4 24 | $-55.2M | $-139.5M | ||
| Q3 24 | $-50.9M | $-133.9M | ||
| Q2 24 | $-63.1M | $-130.6M | ||
| Q1 24 | $-61.9M | $-163.7M |
自由现金流率ALECRVMD
| Q4 25 | — | — | ||
| Q3 25 | -997.6% | — | ||
| Q2 25 | -623.0% | — | ||
| Q1 25 | -1655.0% | — | ||
| Q4 24 | -101.8% | — | ||
| Q3 24 | -332.1% | — | ||
| Q2 24 | -418.6% | — | ||
| Q1 24 | -389.3% | — |
资本支出强度ALECRVMD
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 3.4% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
